Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTraws Pharma Inc

Traws Pharma Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.2524 USD 0.03 ( 13.74%)
Last update at 2026-11-09T18:04:00Z
VOLUME
128007
Market Cap
0.00M

Momentum Score

…

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.22
Low
0.26
High
52 Week Price Range
0.55
Low
1.26
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Traws Pharma Inc is a Nasdaq-listed pharmaceutical company, but publicly available information on its operations and product pipeline is limited. If engaged in drug development, long-term growth drivers may include successful clinical trials, regulatory approvals and partnerships that could support commercialisation and licensing, which may appeal to investors seeking early-stage biotech exposure.
The primary investment risks are limited disclosure combined with typical early-stage pharmaceutical risks such as clinical trial failure, regulatory setbacks and ongoing financing or dilution needs that could materially affect operations and shareholder value.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.22
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-
Net Debt
-20.82M
ROCE
-150.77%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -18.95M -18.96M -16.16M -25.15M -21.49M
Minority interest - - - - 0.00M
Net income -18.95M -18.96M -16.16M -25.16M -21.50M
Selling general administrative 9.09M 8.45M 9.43M 8.33M -
Gross profit 0.21M 0.21M 0.21M 0.23M 2.18M
Reconciled depreciation 0.02M 0.01M 0.01M 0.01M -
Ebit -20.30M -19.63M -16.82M -24.79M -21.70M
Ebitda -20.28M -19.61M -16.80M -24.77M -21.68M
Depreciation and amortization 0.02M 0.01M 0.01M 0.01M 0.01M
Operating income -20.30M -19.63M -16.50M -24.99M -21.70M
Other operating expenses 20.52M 19.85M 16.72M 25.22M 23.88M
Tax provision - - 0.00M 0.00M 0.01M
Income tax expense - - -0.32M 0.00M 0.01M
Total revenue 0.23M 0.23M 0.23M 0.23M 2.18M
Total operating expenses 20.52M 19.85M 16.72M 25.22M 23.87M
Cost of revenue 0.02M 0.01M 0.01M - -
Total other income expense net 1.35M 0.66M 0.33M -0.16M 0.21M
Net income from continuing ops -18.95M -18.96M -16.16M -25.16M -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 22.68M 39.37M 55.48M 19.99M 23.67M
Other current assets 0.40M 0.04M 0.04M 0.18M 0.65M
Total liab 12.01M 11.06M 9.36M 13.81M 12.10M
Total stockholder equity 10.67M 28.31M 46.12M 6.17M 11.57M
Other current liab 3.38M 3.96M 3.13M 4.96M 3.79M
Common stock 0.21M 0.21M 0.21M 0.12M 1.11M
Capital stock 0.21M 0.21M 0.21M 0.12M -
Retained earnings -482.63M -463.68M -444.72M -428.56M -403.40M
Other assets - - - - 0.00M
Cash 20.82M 38.76M 55.07M 19.02M 22.73M
Total current liabilities 9.22M 8.05M 6.12M 10.02M 8.29M
Current deferred revenue 0.23M 0.23M 0.23M 0.23M 0.23M
Net debt -20.82M -38.76M -55.07M -19.02M -22.73M
Other stockholder equity 493.12M 491.82M 490.64M 434.59M 413.88M
Total current assets 22.66M 39.35M 55.43M 19.78M 23.47M
Net receivables 0.02M 0.03M 0.03M 0.04M 0.10M
Inventory 1.42M 0.52M 0.30M 0.54M -
Accounts payable 5.62M 3.86M 2.76M 4.83M 4.27M
Accumulated other comprehensive income -0.02M -0.03M -0.01M 0.01M -0.02M
Non currrent assets other 0.00M 0.00M 0.01M 0.15M 0.15M
Non current assets total 0.02M 0.03M 0.05M 0.20M 0.20M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.01M 0.00M 0.00M -0.01M -
Total cash from financing activities - 0.00M 55.56M 19.36M 26.65M
Net income -18.95M -18.96M -16.16M -25.16M -21.50M
Change in cash -17.94M -16.31M 36.05M -3.70M 5.76M
Begin period cash flow 38.76M 55.07M 19.02M 22.73M 16.97M
End period cash flow 20.82M 38.76M 55.07M 19.02M 22.73M
Total cash from operating activities -17.93M -16.29M -19.49M -23.07M -20.83M
Issuance of capital stock - 0.00M 55.04M 9.06M 21.76M
Depreciation 0.02M 0.01M 0.01M 0.01M 0.01M
Change to inventory -0.01M 0.00M -0.01M -0.06M -
Change to account receivables 0.01M -0.00M 0.01M 0.06M -0.06M
Other cashflows from financing activities -0.01M - - -0.01M -0.06M
Capital expenditures 0.01M 0.00M 0.00M 0.01M 0.06M
Change in working capital -0.30M 1.48M -3.59M 1.49M -0.33M
Stock based compensation 1.30M 1.17M 0.58M 0.37M -
Other non cash items -0.44M 0.10M -0.32M 0.21M 0.84M
Free cash flow -17.95M -16.29M -19.49M -23.09M -20.89M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
TRAW
Traws Pharma Inc		 0.03
13.74%		 0.25 - - - -
NVO
Novo Nordisk A/S		 1.03
2.56%		 41.34 41.58 31.15 2.13 32.99
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12

Profile*

Traws Pharma Inc

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

12 Penns Trail, Newtown, PA, United States, 18940

267 759 3680

https://www.onconova.com

17

Name Title Year Born
Dr. Steven M. Fruchtman M.D. President & Chief Scientific Officer of Oncology 1951
Mr. Mark Patrick Guerin CPA Chief Financial Officer 1969
Dr. Iain D. Dukes DPHIL, M.A., Ph.D. Executive Chairman 1958
Dr. Werner Cautreels Ph.D. CEO & Director 1952
Dr. Nikolay Savchuk Ph.D. COO & Director 1969
Dr. Victor Moyo M.D. Chief Medical Officer NA
Robert Redfield M.D. Chief Medical Officer NA
C. David Pauza Ph.D. Chief Scientific Officer of Virology NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +4.22%

  • Communication Services

    -0.63%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.09%

  • Energy

    +1.91%

  • Financial Services

    +1.64%

  • Healthcare

    +1.58%

  • Industrials

    +3.56%

  • Real Estate

    +0.66%

  • Technology

    +1.84%

  • Utilities

    +1.24%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…